Not currently recruiting at UCLA

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

a study on Breast Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Aditya Bardia, MD, MPH

Description

Summary

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Official Title

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Keywords

Advanced Breast Cancer, First-In-Human, MEN2312, KAT6, Breast Neoplasms, Elacestrant, MEN2312: Monotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants with advanced breast cancer that cannot be cured.
  • Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.
  • Up to 6 prior lines of therapy are allowed. Up to 2 prior chemotherapy and/or cytotoxic antibody-drug conjugates regimens in the advanced/metastatic setting is permitted.

You CAN'T join if...

  • New or active brain metastasis.
  • Severe internal organ spread that could cause immediate life-threatening problems, including large uncontrolled fluid build-up or severe lung or liver involvement.

Note: Other inclusion/exclusion criteria may apply.

Locations

  • UCLA Jonsson Comprehensive Cancer Center not yet accepting patients
    Los Angeles California 90064-2320 United States
  • START Mountain accepting new patients
    West Valley City Utah 84124 United States
  • South Texas Accelerated Research Therapeutics accepting new patients
    San Antonio Texas 78229 United States
  • University of Texas Health Science Center San Antonio not yet accepting patients
    San Antonio Texas 78229 United States

Lead Scientist at UCLA

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Stemline Therapeutics, Inc.
ID
NCT06638307
Phase
Phase 1 Breast Cancer Research Study
Study Type
Interventional
Participants
Expecting 124 study participants
Last Updated